Glaucoma is one of the leading causes of blindness in the world just second to cataract. Decreasing intraocular pressure by filtering surgery combined with antimetabolites(5-fluorouracil, 5-FU; mitomycin C, MMC)is the main way to control the progress of the disease. However, the side effects of these antimetabolites induced limit their clinical use. In recent years, the researchers have turned to the biological modulation of would healing after filtering surgery in order to obtain biological agents with low side effects, target oriented, effect strength and duration controlling. These biological agents include monoclonal antibodies targeting cytokines, matrix metalloproteinases, and gene therapy and so on. Some of them had been applied clinically and demonstrated good results. This is undoubtedly the ideal research direction to the modulation of wound healing after glaucoma filtering surgery.